Bispecific Antibody Therapy

Mechanism

Related News

Lantern Pharma Announces FDA Orphan Drug Designation for LP-284 and USPTO Patent Allowance for LP-184

Jul 24, 2026

Lantern Pharma's LP-284 received FDA Orphan Drug Designation for soft tissue sarcomas, while the USPTO allowed a patent for biomarker-guided use of LP-184 in multiple cancers. LP-284 showed a complete metabolic response in a Phase 1 DLBCL patient, and LP-184 demonstrated a 45% disease control rate in advanced solid tumors.

Major Trials Redefine Treatment Standards for Mantle Cell Lymphoma

Jun 05, 2026

Long-term results from the phase III TRIANGLE trial show ibrutinib-based regimens improve survival in younger mantle cell lymphoma patients, while the ECHO trial establishes a new standard for older patients. Advances in CAR T-cell and bispecific antibody therapies are reshaping treatment for this rare blood cancer. The findings were presented at the annual MCL Consortium meeting.